Valuation : HLS Therapeutics Inc.

Market Cap 80.69M 69.43M 65.15M 59.61M 111M 7.63B 112M 771M 300M 3.9B 303M 296M 12.55B P/E 2026 *
-12.6x
P/E 2027 * -37.3x
Enterprise Value 80.69M 69.43M 65.15M 59.61M 111M 7.63B 112M 771M 300M 3.9B 303M 296M 12.55B EV / Sales 2026 *
1.38x
EV / Sales 2027 * 1.24x
Free-Float
99.46%
Yield 2026 *
-
Yield 2027 * -
1 day-0.28%
1 week-2.70%
Current month-4.00%
1 month-12.62%
3 months-18.74%
6 months-18.18%
Current year-25.31%
1 week 3.58
Extreme 3.58
3.88
1 month 3.56
Extreme 3.56
4.29
Current year 3.56
Extreme 3.56
5.25
1 year 3.56
Extreme 3.56
5.76
3 years 3
Extreme 3
5.76
5 years 3
Extreme 3
20.52
10 years 3
Extreme 3
25.92
Manager TitleAgeSince
Chief Executive Officer 58 01/05/2023
Director of Finance/CFO 61 26/01/2024
Chief Tech/Sci/R&D Officer 61 01/06/2014
Director TitleAgeSince
Director/Board Member 58 12/03/2018
Chairman 48 22/06/2023
Director/Board Member 65 01/01/2021
Date Insider Type Main position Quantity % Market Cap. Importance
20/8/26 Buy

Chief Executive Officer

500 0.0016%
17/8/26 Buy

Chief Executive Officer

2,000 0.0064%
31/7/26 TaxCompany 1,000 0.0032% -
Change 5-day change 1-year change 3-year change Capi.($)
-0.28%-2.70%-33.70%-21.74% 80.69M
-0.37%+3.47%+33.37%+126.31% 108B
+1.27%+5.73%+65.12%+186.05% 57.1B
-0.74%-5.28%-12.94%+238.36% 22.36B
+0.55%+0.12%-11.61%-7.85% 8.12B
+1.22%+0.55%-38.73%-28.02% 7.08B
+0.36%+6.17%+10.67%+26.08% 6.78B
+0.78%-4.09%-16.43%-32.04% 6.1B
-0.42%+0.97%-2.98%+19.57% 5.12B
+1.23%+16.67%+315.92%+478.99% 4.45B
Average +0.34%+1.51%+30.87%+98.57% 22.5B
Weighted average by Cap. +0.17%+1.56%+35.63%+140.07%

Financials

2026 *2027 *
Net sales 58.44M 50.28M 47.18M 43.17M 80.57M 5.52B 81.21M 558M 217M 2.82B 219M 215M 9.09B 65.03M 55.95M 52.5M 48.04M 89.66M 6.15B 90.37M 621M 242M 3.14B 244M 239M 10.12B
Net income -5.47M -4.71M -4.42M -4.04M -7.54M -517M -7.6M -52.24M -20.34M -264M -20.54M -20.09M -851M -2.16M -1.86M -1.75M -1.6M -2.98M -205M -3.01M -20.67M -8.05M -105M -8.13M -7.95M -337M
Net Debt - -
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
04/09/26 CAD 3.600 -0.28% 17,951
02/09/26 CAD 3.610 -3.73% 8,800
01/09/26 CAD 3.750 0.00% 17,400
31/08/26 CAD 3.750 -1.06% 29,107
28/08/26 CAD 3.790 +2.43% 52,047
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.608USD
Average target price
5.286USD
Spread / Average Target
+102.66%

Quarterly revenue - Rate of surprise